Patients with basal-like DCIS are typically treated with radiation and/or lumpectomy without a targeted treatment, and may also face a higher risk of disease recurrence.1,81 As such, these patients might benefit from CCR2 and MET targeted therapy to reduce this risk. The gene discussed is CCR2; the disease is ductal breast carcinoma in situ.